KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Receivables readings, the most recent being $14.7 million for Q4 2025.

  • On a quarterly basis, Receivables rose 23.92% to $14.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.7 million, a 23.92% increase, with the full-year FY2025 number at $14.7 million, up 23.92% from a year prior.
  • Receivables hit $14.7 million in Q4 2025 for Ginkgo Bioworks Holdings, down from $21.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $178.1 million in Q2 2022 to a low of $370000.0 in Q1 2024.
  • Median Receivables over the past 5 years was $21.8 million (2025), compared with a mean of $49.0 million.
  • Biggest five-year swings in Receivables: crashed 99.56% in 2024 and later soared 7006.22% in 2025.
  • Ginkgo Bioworks Holdings' Receivables stood at $136.1 million in 2021, then crashed by 98.86% to $1.6 million in 2022, then skyrocketed by 595.89% to $10.8 million in 2023, then increased by 9.63% to $11.9 million in 2024, then grew by 23.92% to $14.7 million in 2025.
  • The last three reported values for Receivables were $14.7 million (Q4 2025), $21.4 million (Q3 2025), and $22.2 million (Q2 2025) per Business Quant data.